2019
DOI: 10.1007/s10989-019-09951-y
|View full text |Cite
|
Sign up to set email alerts
|

Insilico Alpha-Helical Structural Recognition of Temporin Antimicrobial Peptides and Its Interactions with Middle East Respiratory Syndrome-Coronavirus

Abstract: Many antimicrobial peptides (AMPs) have multiple antimicrobial immunity effects. One such class of peptides is temporins. Temporins are the smallest (AMPs) found in nature and are highly active against gram-positive bacteria. Nowadays, there was a rapid increase in the availability of the 3D structure of proteins in PDB (protein data bank). The conserved residues and 3D structural conformations of temporins (AMPs) were still unknown. The present study explores the sequence analysis, alpha-helical structural co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(16 citation statements)
references
References 46 publications
(42 reference statements)
0
14
0
Order By: Relevance
“…According to recent research, the lipopeptide EK1C4, derived from EK1 (SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL), is the most effective fusion inhibitor against COVID-19 S protein-mediated membrane fusion ( Xia et al, 2020 ). Homology modeling and protein-peptide docking showed that temporin has potential therapeutic applications against MERS-CoV ( Marimuthu et al, 2019 ). Two AMPs from the non-structural protein nsp10 of SARS-CoV, K12, and K29, can inhibit SARS-CoV replication ( Ke et al, 2012 ).…”
Section: Classification Of Ampsmentioning
confidence: 99%
“…According to recent research, the lipopeptide EK1C4, derived from EK1 (SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL), is the most effective fusion inhibitor against COVID-19 S protein-mediated membrane fusion ( Xia et al, 2020 ). Homology modeling and protein-peptide docking showed that temporin has potential therapeutic applications against MERS-CoV ( Marimuthu et al, 2019 ). Two AMPs from the non-structural protein nsp10 of SARS-CoV, K12, and K29, can inhibit SARS-CoV replication ( Ke et al, 2012 ).…”
Section: Classification Of Ampsmentioning
confidence: 99%
“…However, no previous studies have reported the interaction of AMPs with SARS-CoV-2 target proteins. In this respect, some studies have previously evaluated the activity of natural and synthetic peptides, including defensins, plectasins, temporins and cathelicidins, against multiple respiratory viruses, such as influenza A virus H5N1, H1N1, MERS-CoV, and SARS-CoV [ 27 , 28 , 29 , 39 , 40 , 57 ]. Similar to this study, in silico analyses showed the potent antiviral effects of AMPs against Betacoronavirus [ 27 , 39 ].…”
Section: Resultsmentioning
confidence: 99%
“…In this respect, some studies have previously evaluated the activity of natural and synthetic peptides, including defensins, plectasins, temporins and cathelicidins, against multiple respiratory viruses, such as influenza A virus H5N1, H1N1, MERS-CoV, and SARS-CoV [ 27 , 28 , 29 , 39 , 40 , 57 ]. Similar to this study, in silico analyses showed the potent antiviral effects of AMPs against Betacoronavirus [ 27 , 39 ]. According to our results, the AMPs are attractive candidates as alternative to conventional antiviral drugs to control SARS-CoV-2 infection, because they offer several potential advantages, including specific anti-CoV effects, high selectivity, and do not be associated with severe adverse effects according to in vitro and in vivo assays [ 58 , 59 , 60 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The six amino acid residues N-myristoylated-peptide, from larval hemolymph of the tobacco budworm Heliothis virescens , is active against HIV-1 and HSV-1 [ 62 ]. An homology modeling study demonstrated that temporins may provide therapeutic applications against MERS-CoV [ 63 ]. The antiviral activity of defensins has been widely demonstrated against several viruses, including HIV, influenza virus, human adenovirus, severe acute respiratory syndrome coronavirus (SARSC), papillomavirus (HPV), respiratory syncytial virus (RSV), and herpes simplex virus (HSV) [ 64 ].…”
Section: Novel Approachesmentioning
confidence: 99%